Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 10/20 | 0.40 |
| ▸ | LOX | P28300 | 3/20 | 0.40 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27115679 | 0.87 | LOXL2 (0.36) | LOXL2LOXLOXL3NOS3NOS1 | |
| SCHEMBL27113643 | 0.86 | LOXL2 (0.47) | LOXL2LOXLOXL3NOS3NOS1 | |
| SCHEMBL27112912 | 0.84 | CYP1A2 (0.42) | NOS3NOS1NOS2ADRB2KDM5C | |
| SCHEMBL18880283 | 0.81 | PRMT6 (0.42) | LOXL2LOXLOXL3NOS3NOS1 | |
| SCHEMBL25488487 | 0.80 | NOS3 (0.58) | NOS3NOS1NOS2ADRB2 | |
| SCHEMBL14867653 | 0.78 | UHRF1 (0.43) | NOS2ADRB2 | |
| SCHEMBL27112913 | 0.76 | NOS3 (0.48) | NOS3NOS1NOS2ADRB2KDM5C | |
| SCHEMBL4107151 | 0.76 | LOXL2 (0.61) | LOXL2LOXLOXL3NOS3NOS1 | |
| SCHEMBL15200880 | 0.75 | NOS3 (0.61) | LOXL2LOXLOXL3NOS3NOS1 | |
| SCHEMBL8117393 | 0.75 | L3MBTL1 (0.47) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | LOXL2 3259/4885LOX 2179/4885LOXL3 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.